<DOC>
	<DOCNO>NCT02362789</DOCNO>
	<brief_summary>The study design explore kinetics psoriasis symptom , pruritus intensity lesional biomarkers 16 week treatment 300 mg secukinumab patient moderate severe psoriasis high pruritus involvement baseline . For patient achieve extensive remission define PASI response 98-100 % , kinetics psoriasis pruritus symptom explore randomized withdrawal phase 16 week . Biopsies take investigate lesional biomarkers related pathogenesis pruritus psoriasis patient .</brief_summary>
	<brief_title>Secukinumab Study PSOriasis Exploring pruRITUS Intensity Lesional Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Chronic moderate severe plaque type psoriasis diagnose qualified physician least 6 month prior baseline PASI score &gt; 10 baseline . Psoriasis patient pruritus intensity â‰¥ 30 100point VAS , recall period 24h part PGACP , , screen baseline . Key Underlying condition psoriasis opinion investigator currently cause influence pruritus skin ( e.g . drug induce pruritus , renal insufficiency , diabetes ) . Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic , guttate ) screening study start . Ongoing use prohibit psoriasis nonpsoriasis treatment . Washout period adhere . If use prohibit treatment require , subject may include study . Pregnancy , breast feeding inadequate contraception ( necessary )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>